Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 8/20 | 0.68 |
| ▸ | CDK8 | P49336 | 8/20 | 0.68 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.48 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.45 |
| ▸ | AXL | P30530 | 1/20 | 0.45 |
| ▸ | CLK2 | P49760 | 2/20 | 0.43 |
| ▸ | CLK1 | P49759 | 1/20 | 0.43 |
| ▸ | CLK3 | P49761 | 1/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.43 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.43 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.43 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.39 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.39 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.39 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.39 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26113876 | 0.87 | CCNC (0.63) | CCNCCDK8CYP46A1DYRK1ANEK1 | |
| SCHEMBL16115990 | 0.85 | CCNC (0.65) | CCNCCDK8IMPDH2 | |
| SCHEMBL26110779 | 0.84 | NEK1 (0.53) | CCNCCDK8DYRK1ANEK1HTT | |
| SCHEMBL30590619 | 0.84 | NEK1 (0.53) | CCNCCDK8DYRK1ANEK1HTT | |
| SCHEMBL16115895 | 0.84 | CCNC (0.68) | CCNCCDK8CYP46A1DYRK1ANEK1 | |
| SCHEMBL16115221 | 0.83 | CCNC (0.74) | CCNCCDK8DYRK1AIMPDH2CLK2 | |
| SCHEMBL16116379 | 0.81 | CCNC (1.00) | CCNCCDK8DYRK1AIMPDH2CLK2 | |
| SCHEMBL6370434 | 0.78 | HTR3A (0.47) | CCNCCDK8CYP46A1NEK1 | |
| SCHEMBL6377962 | 0.78 | HTR3A (0.47) | CCNCCDK8CYP46A1NEK1 | |
| SCHEMBL31555567 | 0.72 | IMPDH2 (0.57) | CCNCCDK8IMPDH2PKN1PKN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459951-B2 | Compounds that interact with RAS superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY THERAPEUTICS, LLC (US) | 2025-11-04 | — | — | US | disclosed |
| CN-119365460-A | Compounds that interact with Ras superfamily proteins for the treatment of cancer, inflammatory diseases, RAS diseases, and fibrotic diseases | 尚医治疗有限责任公司 | 2025-01-24 | — | — | CN | disclosed |
| US-20240360141-A1 | COMPOUNDS THAT INTERACT WITH RAS SUPERFAMILY PROTEINS FOR TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY THERAPEUTICS, LLC | 2024-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459951-B2 | Compounds that interact with RAS superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | KRAS, HRAS, NRAS | CCNC 1245/4885CDK8 1559/4885CYP46A1 2029/4885 |
| US-20240360141-A1 | COMPOUNDS THAT INTERACT WITH RAS SUPERFAMILY PROTEINS FOR TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | KRAS, HRAS, NRAS | CCNC 1245/4885CDK8 1559/4885CYP46A1 2029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.